Aldeyra Therapeutics to Join the Russell 2000® and Russell 3000® Indexes
23 June 2023 - 9:00PM
Business Wire
(Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to
discovering and developing innovative therapies designed to treat
immune-mediated diseases, today announced that it will be added to
the Russell 2000® and the Russell 3000® indexes, effective after
the U.S. equity markets close on June 23, 2023.
Annual Russell indexes reconstitution captures the 4,000 largest
US stocks as of April 28 2023, ranking them by total market
capitalization, including both the Russell 3000® and Russell
Microcap® Indexes. Membership in the US all-cap Russell 3000®
Index, which remains in place for one year, means automatic
inclusion in the large-cap Russell 1000® Index or small-cap Russell
2000® Index as well as the appropriate growth and value style
indexes. FTSE Russell determines membership for its Russell indexes
primarily by objective, market-capitalization rankings and style
attributes.
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $12.1 trillion in
assets are benchmarked to or invested in products based on the
Russell U.S. indexes. Russell indexes are part of FTSE Russell, a
leading global index provider.
About Aldeyra
Aldeyra Therapeutics is a biotechnology company devoted to
discovering innovative therapies designed to treat immune-mediated
diseases. Our approach is to develop pharmaceuticals that modulate
immunological systems, instead of directly inhibiting or activating
single protein targets, with the goal of optimizing multiple
pathways at once while minimizing toxicity. Our product candidates
include RASP (reactive aldehyde species) modulators ADX‑629,
ADX‑246, ADX‑248, and chemically related molecules for the
potential treatment of systemic and retinal immune-mediated
diseases. Our pre-commercial product candidates are reproxalap, a
RASP modulator for the potential treatment of dry eye disease
(under U.S. Food and Drug Administration New Drug Application
Review) and allergic conjunctivitis, and ADX-2191, a novel
formulation of intravitreal methotrexate for the potential
treatment of proliferative vitreoretinopathy and retinitis
pigmentosa.
Safe Harbor Statement
This release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Aldeyra intends such forward-looking statements to be covered by
the safe harbor provisions for forward-looking statements contained
in Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995. In some cases,
you can identify forward-looking statements by terms such as, but
not limited to, “may,” “might,” “will,” “objective,” “intend,”
“should,” "could," “can,” “would,” “expect,” “believe,”
“anticipate,” “project,” “on track,” “on schedule,” “target,”
“design,” “estimate,” “predict,” “potential,” “aim,” “plan,” or the
negative of these terms, and similar expressions intended to
identify forward-looking statements. Such forward-looking
statements are based upon current expectations that involve risks,
changes in circumstances, assumptions, and uncertainties. Important
factors that may cause actual results to differ material from those
reflected in Aldeyra’s forward-looking statements, include, among
others, the factors that are described in the “Risk Factors” and
“Management's Discussion and Analysis of Financial Condition and
Results of Operations” sections of Aldeyra's Annual Report on Form
10-K for the year ended December 31, 2022, and Aldeyra’s Quarterly
Report on Form 10-Q for the quarter ended March 31, 2023, which are
on file with the Securities and Exchange Commission (SEC) and
available on the SEC's website at https://www.sec.gov/. Additional
factors may be described in those sections of Aldeyra's Quarterly
Report on Form 10-Q for the quarter ended June 30, 2023, expected
to be filed with the SEC in the third quarter of 2023.
In addition to the risks described above and in Aldeyra's other
filings with the SEC, other unknown or unpredictable factors also
could affect Aldeyra's results. No forward-looking statements can
be guaranteed, and actual results may differ materially from such
statements. The information in this release is provided only as of
the date of this release, and Aldeyra undertakes no obligation to
update any forward-looking statements contained in this release on
account of new information, future events, or otherwise, except as
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230623965905/en/
Investor & Media: David Burke Tel: (917) 618-2651
investorrelations@aldeyra.com
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Apr 2024 to May 2024
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From May 2023 to May 2024